Previous reports from this laboratory have demonstrated that L-leucine-induced hypoglycemia can be experimentally produced in normal dogs during periods of either exogenous (1) or endogenous (2) hyperinsulinism. On the basis of these experiments, it was suggested that L-leucine acts to inhibit hepatic glucose output and that "leucine hypoglycemia" occurs in situations where increased hepatic glucose output is necessary for maintenance of euglycemia. To extend these observations of experimental leucine hypoglycemia, it seemed desirable to investigate the effect of L-leucine in other situations characterized by hypoglycemia, hyperinsulinism, or both. Consequently, we have measured the blood glucose response to L-leucine at varying intervals after both the acute and chronic administration of chlorpropamide. ter a single oral dose of chlorpropamide, 4) 24 hours after 3 consecutive days -of the same oral dose of chlorpropamide, given once daily, and 5) without chlorpropamide pretreatment.
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Chlorpropamide was given in a dose of 250 or 375 mg. All dogs weighing less than 10 kg were arbitrarily given 250 mg, and 375 mg was used in dogs weighing over 10 kg. Each experiment was performed as follows. A dog was anesthetized with pentobarbital, and two blood samples were drawn 15 minutes apart for glucose determination, with the average of these two values used as a baseline. Then 30 mmoles of L-leucine in 200 ml of distilled water or an equal volume of 0.45 per cent NaCl was given by an intravenous infusion lasting approximately 15 minutes. Blood was then drawn for measurement of glucose concentration 30 and 60 minutes after L-leucine or saline had been administered. The results have been expressed as percentage of fall in glucose concentration (100 X maximal fall observed in blood glucose concentration divided by the baseline value). The percentage of fall in blood glucose due to L-leucine in any given dog under each experimental condition is then expressed as follows: maximal fall in blood glucose after leucine X 100/average baseline minus maximal fall in blood glucose after saline X 100/average baseline. Blood glucose was measured by the Somogyi method as modified by Nelson (3) .
Serum chlorpropamide levels were measured in eight individual experiments by the method of Toolan and Wagner (4) . B . Effect of L-leucine on hepatic metabolism 1. Effect of L-leucine on hepatic-vein and fentoral-vein blood glucose concentration in dogs without prior pretreatment. Five experiments were performed with the following protocol. After the induction of anesthesia with pentobarbital, a radio-opaque catheter was passed percutaneously into the vena cava from the femoral vein and inserted in a hepatic vein under fluoroscopic control. A second catheter was placed in the other femoral vein for collection of peripheral venous blood. After three blood samples were drawn from each catheter over a 15-minute period, each dog received a rapid intravenous infusion of 30 mM of L-leucine in 200 ml of distilled water. Paired blood samples were then drawn from each catheter every 10 minutes for the next 60 minutes. The location of the catheter in the hepatic vein was established before each sample was taken. Blood glucose was measured by the iodometric technique of Somogyi (5, 6 
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-. 00 00 .- 3. Effect of L-leucine on hepatic-vein, fentoral-vein, and femoral-artery blood glucose concentration in dogs with portacaval shunt. Three experiments were performed on dogs in which end-to-side portacaval shunts had been performed several weeks previously. In each of these experiments the dogs were studied 4 hours after a single oral dose of chlorpropamide. In addition to the previously described catheters in the hepatic and femoral veins, a catheter was also passed percutaneously into the femoral artery, and blood was sampled from all three of these catheters for determination of blood glucose concentration. In this series of experiments, hepatic blood flow was also estimated by the bromsulphalein (BSP) extraction method of Bradley, Ingelfinger, Bradley, and Curry (7). Bromsulphalein was measured by a modification (8) of the method of Rosenthal and White (9) . In other respects, the protocols for these experiments were as described previously. The blood glucose response of each dog to L-leucine under the five experimental conditions is listed in Table I , and the mean hypoglycemic response of all dogs is illustrated in Figure 1 . The data were pooled and a single standard error of 4.10 was calculated for each mean. Three conclusions may be drawn from these experiments. First, L-leucine by itself produces a modest but statistically significant fall in blood glucose concentration (p < 0.03). Second, the mean hypoglycemic response to L-leucine 2 and 12 hours after a single oral dose of chlorpropamide is significantly greater than that due to L-leucine alone. Finally, the mean hypoglycemic response to L-leucine in the same dogs receiving chlorpropamide on a chronic basis is significantly less than that 2 to 12 hours after one acute dose, and no greater than that produced by L-leucine alone. The comparison between means was made by the method of the 5 per cent least significant difference (10) , in which means that differed by more than 11.7 were significant at the 0.05 level.
It appears unlikely that the diminished response to L-leucine 24 hours after 3 consecutive days of chlorpropamide pretreatment results from a decrease in the degree of hypoglycemia produced by chlorpropamide. First, baseline blood glucose concentration was as low after the chronic administration of chlorpropamide as it was after one acute dose. Second, the serum levels of chlorpropamide 24 hours after 3 days of chlorpropamide administration were as high as those measured 2 hours after chlorpropamide (Table II) . Although there was no significant difference between the measured chlorpropamide levels, the leucine effect was more impressive in the 2-hour group. B. The effect of L-leucine on hepatic mnetabolismn
1. L-Leucine alone. L-Leucine produced a small but consistent decrease in blood glucose concentration of every dog, studied (Table III) . Although there was considerable variation from time minutes after L-leucine were compared with mean baseline values and found to be significantly decreased (t test, p < 0.01). Although the mean HV-FV glucose concentration difference was decreased at these times, it remained significantly positive.
2. L-Leiucine given 4 hours after chlorpropamnide.
The effect of L-leucine or saline on blood glucose concentration of each dog studied is seen in Table IV . L-Leucine consistently lowered blood glucose concentration of both hepatic and femoral veins, whereas saline had no significant effect. The mean response of all dogs receiving L-leu-First, the hypoglycemic response to L-leucine 4 cine after chlorpropamide pretreatment is illus-hours after chlorpropamide is much greater than trated in Figure 3 . Table V and are similar to those observed under the same conditions in intact dogs, i.e., hypoglycemia produced by L-leucine was accompanied by a marked fall in HV-FV and HV-HA (hepatic-artery) blood glucose differences. In addition, estimated hepatic blood flow was shown not to change appreciably after L-leucine administration, and consequently net hepatic glucose output was markedly reduced during hypoglycemia. The observation that L-leucine does not affect hepatic blood flow was also confirmed in 3 other dogs by use of a noncannulating, square-wave, electromagnetic flowmeter ( 11 ) .2 Consequently it appears unlikely that the changes in HV-FV blood glucose concentrations in intact dogs could have resulted from increased splanchnic glucose utilization, and they indicate further that the effect of L-leucine is to inhibit mechanisms for the maintenance of hepatic glucose output.
DISCUSSION
Any theory attempting to explain the mechanism of leucine hypoglycemia must take into account two fundamental characteristics of this phenomenon.
First, although the results we have described demonstrate that L-leucine can lower slightly the blood glucose concentration of normal subjects, significant hypoglycemia has only been produced in certain patients with idiopathic infantile hypoglycemia (12), or insulin-secreting tumors of the pancreas (13) , or in normal men (14) and dogs pretreated with insulin (1) or chlorpropamide. Second, the response to L-leucine is not uniform in these situations and cannot be demonstrated in all patients with these clinical syndromes (15) (16) (17) (18) (19) , nor, as we have shown, in all dogs pretreated with chlorpropamide. Since all the situations in which L-leucine had produced a significant hypoglycemic response seemed to 2 These measurements were obtained with the aid of Dr. S. Kountz, Department of Surgery, Stanford University School of Medicine, Palo Alto, Calif. share in common hyperinsulinism, or hypoglycemia, or both, we had suggested earlier that L-leucine "decreases the hyperglycemic response to hypoglycemia, specifically, hepatic glucose output' (1). The present demonstration that net hepatic glucose output is markedly reduced during hypoglycemia produced by L-leucine supports this thesis. On the other hand, even if it is assumed that L-leucine produces hypoglycemia by inhibiting hepatic glucose output during hypoglycemic stress, it is difficult to explain the variable response to L-leucine in what appear to be identical situations.
An attempt to solve this dilemma has been made by differentiating between patients who are "leucine-sensitive" and those who are "leucineinsensitive" (20) . Implicit in this distinction is the assumption that these two categories are reflections of different disease processes, and that patients can be separated on the basis of their response to L-leucine. Since the etiology or etiologies of idiopathic infantile hypoglycemia are obscure, the merit of a distinction based on the patient's response to L-leucine is difficult to evaluate. On the other hand, the distinction between "leucine-sensitive" and "leucine-insensitive" seems to have little meaning when applied to patients with insulin-secreting tumors of the pancreas, and avoids the question of why L-leucine produces hypoglycemia only in some patients with organic hyperinsulinism (15) (16) (17) . This problem is not confined to clinical situations, and it is as difficult to account for the variable hypoglycemic response to L-leucine that has been observed in experimental leucine hypoglycemia. The administration of L-leucine to normal dogs, as to normal men, does not elicit significant hypoglycemia. In contrast, if L-leucine is administered within 2 to 12 hours after a single oral dose of chlorpropamide, normal dogs, like "leucine-sensitive" patients, demonstrate a significant hypoglycemic response. Furthermore, when L-leucine was given to normal dogs who had received chlorpropamide chronically, there was only a modest fall in blood glucose concentration, similar to that described in "leucine-insensitive" patients. Although the analogies are obvious, it is clear that they are only analogies. On the other hand, the conditions under which experimental leucine hypoglycemia has been studied were varied purposefully, and it is possible that a more detailed analysis of these ex-periments may prove helpful in explaining the considerable variation in the hypoglycemic effect of L-leucine.
In the experiments described, two basic patterns of response to L-leucine were demonstrated. A normal dog receiving L-leucine exhibited a small fall in blood glucose concentration. The same dog, given the same amount of L-leucine 2 hours after a single oral dose of chlorpropamide, demonstrated a significantly greater hypoglycemic response. In the first instance, normal dogs are not reacting to any hypoglycemic stimulus, and it might be predicted that the ability of L-leucine to inhibit hepatic glucose output would result in only a minor fall in blood glucose concentration. The degree, however, of hypoglycemic stress in a normal dog 2 hours after 250 to 375 mg of chlorpropamide is certainly greater, and in this case, inhibition of hepatic glucose output could possibly result in a much greater fall in blood glucose concentration.
On the other hand, it is clear that the degree of hypoglycemia produced by L-leucine is not directly related to the severity of the hypoglycemic stimulus alone. For example, dogs receiving chlorpropamide chronically were, if anything, reacting to a more profound hypoglycemic stimulus than were dogs 2 hours after a single oral dose of chlorpropamide. Yet the administration of L-leucine to dogs after chronic chlorpropamide pretreatment elicited a fall in blood glucose concentration no greater than that observed after L-leucine alone. Perhaps the explanation for the diminished effect of L-leucine in normal dogs after chronic pretreatment with chlorpropamide is that the counter-regulatory mechanisms for the maintenance of euglycemia had been so well stimulated that it was more difficult to produce hypoglycemia in this case. Obviously there are insufficient data to explain precisely why L-leucine acts differently under certain conditions. On the other hand, it is clear that different hypoglycemic responses to L-leucine can occur in the same subject under different conditions, and it is difficult in the light of these observations to view "leucine sensitivity" as an "inborn error of metabolism." It seems more reasonable to assume that the specific metabolic action of L-leucine is relatively constant under all conditions and that only the resultant fall in blood glucose concentration varies from situation to situation. Finally, it would appear that a more thorough understanding of the various mechanisms by which the liver maintains euglycemia is essential for ultimate understanding of the phenomenon of leucine hypoglycemia.
SUMMARY
The administration of L-leucine alone to normal dogs slightly lowered blood glucose concentration, which was greatly increased after suitable pretreatment with chlorpropamide. Experiments performed on both intact dogs and dogs with portacaval shunt have indicated that this augmented hypoglycemic response to L-leucine after chlorpropamide is accompanied by a marked decrease in positive hepatic glucose balance. It is suggested that L-leucine acts similarly in all situations to inhibit hepatic glucose output and that the resultant fall in blood glucose concentration will vary considerably, depending on the status of other homeostatic mechanisms for maintenance of eugl--cemia at the time L-leucine is administered.
